Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Control group: Patients in groups of 30 for a period of two months Placebo 2 times a day will be prescribed. Intervention 2: Intervention group: Patients in groups of 30 for a period o
nanomicelles) to 80 mg 2 times a day will be prescribed.
Placebo
Treatment - Drugs
Control group: Patients in groups of 30 for a period of two months Placebo 2 times a day will be prescribed
Intervention group: Patients in groups of 30 for a period of two months curcumin(Sinacurcumin
nanomicelles) to 80 mg 2 times a day will be prescribed
Sponsors
Vice Chancellor for research of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. having ALT and AST upper than highest normal level 2. have at least one of the following: A) Diabetes B) Hyperlipidemia C) Obesity 3. The age of 15 to 60 Exclusion criteria: 1. Alcohol consumption 2. Get a positive serology of viral hepatitis 3. ANA or AMA positive test, Alpha1 Antitrypsin, Low serum levels of Seroloplasin or high levels of antibodies of ASMA or LKM. 4. High ferritin 450 or Iron/TIBC> 45% 5. The patient before the intervention or during the intervention, affected with acute or chronic disease that causes in LFT disorders. 6.The patient before the intervention or during the intervention is consuming medicine that potentially capable of Disrupting the LFT. 7. Pregnancy 8. Patients Younger than 15 or older than 60.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMI. Timepoint: Before and two months after intervention. Method of measurement: Measuring the weight by Scale and height by Metre.;ALT. Timepoint: Before and two months after intervention. Method of measurement: Serology.;AST. Timepoint: Before and two months after intervention. Method of measurement: Serology.;ALP. Timepoint: Before and two months after intervention. Method of measurement: Serology.;TG. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Total Cholestrol. Timepoint: Before and two months after intervention. Method of measurement: Serology.;HDL. Timepoint: Before and two months after intervention. Method of measurement: Serology.;FBS. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Serum Insulin. Timepoint: Before and two months after intervention. Method of measurement: Serology.;LDL. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Total Bilirubin. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Direct Bilirubin. Timepoint: Before and two months after intervention. Method of measurement: Serology. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDR Beheshti Namdar, Ali
Mashhad University of Medical Sciences
Outcome results
None listed